Last reviewed · How we verify
Placebo (for Esomeprazole)
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.
A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes. Used for Control arm in esomeprazole clinical trials (not a therapeutic indication).
At a glance
| Generic name | Placebo (for Esomeprazole) |
|---|---|
| Also known as | placebo |
| Sponsor | University of Malaya |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials. Any observed effects result from patient expectation, the therapeutic context, and natural disease progression rather than direct molecular action. In this case, it serves as a control comparator for esomeprazole efficacy studies.
Approved indications
- Control arm in esomeprazole clinical trials (not a therapeutic indication)
Common side effects
Key clinical trials
- Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial (PHASE4)
- Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy (PHASE2)
- Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication (PHASE4)
- Effect of Dexlansoprazole on Bone Homeostasis (PHASE1)
- Esomeprazole to Reduce Organ Failure in Sepsis (PHASE3)
- Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori (PHASE3)
- PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms (PHASE4)
- A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Esomeprazole) CI brief — competitive landscape report
- Placebo (for Esomeprazole) updates RSS · CI watch RSS
- University of Malaya portfolio CI